Check patentability & draft patents in minutes with Patsnap Eureka AI!

2-hydroxypropyl-beta-cyclodextrin (hp[beta]cd) for use in the treatment of breast cancer

A technology of hydroxypropyl and cyclodextrin, which is applied in the field of triple-negative breast cancer and HPβCD for the treatment of triple-negative breast cancer, can solve the problems of access to drugs, no recovery, and few patients

Pending Publication Date: 2021-10-01
UNIVERSITY OF THE WITWATERSRAND
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, commonly used pharmaceutical active ingredients (APIs) designed to target such receptors are ineffective
There are no known effective treatments for triple-negative breast cancer, so patients have little or no chance of recovery
[0005] This is particularly detrimental among African and Asian populations, where access to medicines is often hindered and poverty exacerbates lack of access to medicines and treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2-hydroxypropyl-beta-cyclodextrin (hp[beta]cd) for use in the treatment of breast cancer
  • 2-hydroxypropyl-beta-cyclodextrin (hp[beta]cd) for use in the treatment of breast cancer
  • 2-hydroxypropyl-beta-cyclodextrin (hp[beta]cd) for use in the treatment of breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0113] The following examples are not intended to limit the scope of the invention in any way, but merely provide examples and / or illustrate certain embodiments of the invention.

[0114] The cytotoxic activity of HP[beta]CD was tested in four different cell lines constituting the in vitro study. The four cell lines are: estrogen-positive (ER+) MCF7 breast cancer cells, triple-negative MDA-MB-231 breast cancer cells, MRC-5 (normal human lung fibroblasts), and HEK-293 (normal human embryonic kidney cells ). Cytotoxicity, apoptosis and cholesterol based assays were performed in vitro. The result is shown below. In vivo studies (mouse model) are also presented, and additional studies on ER+ and triple negative breast cancer cells are envisioned. Based on preliminary studies (in vitro and in vivo), the combined mechanism of action will be elucidated.

[0115] Cells were incubated in an appropriate medium supplemented with 10% FCS, penicillin (100 U / ml) and streptomycin (100 μg / m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to 2-hydroxypropyl-beta-cyclodextrin (HP[beta]CD) for use in the treatment of breast cancer. Particularly, this invention relates to HP[beta]CD for use in the treatment of triple negative breast cancer, wherein the HP[beta]CD is for administration to a patient in need thereof. The invention extends to methods of preparing a pharmaceutical composition comprising HP[beta]CD, and further extends to a method of treating breast cancer, typically triple negative breast cancer, by administration of said composition to a patient in need thereof.

Description

technical field [0001] The present invention relates to 2-hydroxypropyl-β-cyclodextrin (HPβCD) for use in the treatment of breast cancer. In particular, the present invention relates to HP[beta]CD for use in the treatment of triple-negative breast cancer, wherein HP[beta]CD is administered to a patient in need thereof. The invention extends to a method of preparing a pharmaceutical composition comprising HP[beta]CD, and additionally to a method of treating breast cancer, typically triple negative breast cancer, by administering said composition to a patient in need thereof. Background technique [0002] Cancer is one of the leading causes of death worldwide. According to WHO, the number of new cancer cases worldwide is expected to increase by about 70% in the next two decades. Breast cancer is one of the most common malignant tumors in women worldwide, with nearly 1.7 million new cases in 2012. In 2012, more than 8000 new cases of breast cancer were diagnosed in South Afr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P35/00A61K31/724
CPCA61K31/724A61P35/00
Inventor 曼迪普·考尔苏拉尼·塔鲁·萨哈
Owner UNIVERSITY OF THE WITWATERSRAND
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com